Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 4/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.31 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27649171 | 0.80 | HDAC1 (0.35) | MAPTTP53SMN1; SMN2HDAC1HDAC3 | |
| SCHEMBL5650058 | 0.80 | L3MBTL1 (0.42) | MAPTTP53SMN1; SMN2RXFP1KDM4E | |
| SCHEMBL5649734 | 0.79 | F2 (0.41) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5648163 | 0.78 | OPRK1 (0.40) | SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL5652709 | 0.78 | ALDH1A1 (0.36) | SMN1; SMN2KDM4ELMNAKMT2A | |
| SCHEMBL5652857 | 0.77 | — | — | |
| SCHEMBL5647632 | 0.77 | PTGS2 (0.34) | MAPTKAT2BPTGS2LMNAHPGD | |
| SCHEMBL5650827 | 0.77 | VNN1 (0.37) | HDAC1HDAC3LMNA | |
| SCHEMBL5648431 | 0.77 | FDPS (0.31) | — | |
| SCHEMBL27649114 | 0.77 | F2 (0.36) | MAPTTP53SMN1; SMN2NPSR1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1713774-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075424-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | PLG, F2, PLAT | MAPT 4569/4885TP53 2362/4885SMN1; SMN2 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.